Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseasesNathan A. Berger, Csaba Szabó, A. Hamid Boulares et al.|British Journal of Pharmacology|2017Cited by 210
Activation of mitochondrial fusion provides a new treatment for mitochondria-related diseasesAlíz Szabó, Balázs Sümegi|Biochemical Pharmacology|2018Cited by 97
PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1α, Nrf2, and NFκBKrisztina Kovács, Balázs Sümegi|Investigative Ophthalmology & Visual Science|2019Cited by 39
PARP Inhibition Attenuates Acute Kidney Allograft Rejection by Suppressing Cell Death Pathways and Activating PI-3K-Akt CascadeK. Kalmár-Nagy, Balázs Sümegi|PLoS ONE|2013Cited by 17